(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) Friday said it has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus in around 70 countries globally ...

AstraZeneca on Friday announced that it would sell the commercial rights to two hypertension medicines, Atacand and Atacand Plus, to German pharmaceutical company Cheplapharm Arzneimittel GmbH, for ...

FILE PHOTO: A test tube labelled with the vaccine is seen in front of AstraZeneca logo in this illustration taken (Reuters) - AstraZeneca Plc <AZN.L> said on Friday it would sell commercial rights for ...

AstraZeneca Plc AZN announced that it has sold its European rights to Atacand and Atacand Plus to Cheplapharm Arzneimittel for $210 million. Per the terms of the agreement, AstraZeneca will receive ...

AstraZeneca PLC said Friday that it has agreed to sell commercial rights to its Atacand and Atacand Plus drugs in around 70 countries to Cheplapharm Arzneimittel GmbH for $400 million. The British ...

The total value of all payments for the Atacand brand is $400m AstraZeneca has completed the divestment of the rights to its heart failure and hypertension brand Atacand (candesartan cilexetil) in ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) Tuesday said it has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of ...

Cheplapharm will pay AstraZeneca a total of $400m in non-contingent consideration, of which the present value will be recognised as Other Operating Income upon completion of the transaction, ...

(Sharecast News) - AstraZeneca has agreed to sell the commercial rights to Atacand - candesartan cilexetil - and Atacand Plus - a fixed-dose combination of candesartan cilexetil and ...

March 3, 2005 — The U.S. Food and Drug Administration (FDA) has approved candesartan cilexitil for use in chronic heart failure with left ventricular dysfunction to reduce the risk of mortality and ...

AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries. AstraZeneca is selling rights ...

AstraZeneca PlcAZN announced that it has sold its European rights to Atacand and Atacand Plus to Cheplapharm Arzneimittel for $210 million. Per the terms of the agreement, AstraZeneca will receive ...